Sanofi US
2024 Co-Op MSAT Recombinant Platform - DSP
This job is now closed
Job Description
- Req#: R2736395
Work on an MSAT development project, to include execution of chromatography and filtration operations, protein stability studies, analytical testing, and data analysis.
Collaborate with the MSAT project team; attend regular team meetings and share study progress and results.
Participate in design and execution of experiments using small-scale models, analyze and interpret results, and recommend additional experiments.
Author internal presentations, protocols, and technical reports, as applicable.
Pursuing a Bachelor’s (sophomore year or higher) or Master’s degree in Chemical Engineering, Biochemistry, Biotechnology, or related discipline.
Experience in a biotechnology or pharmaceutical industry laboratory setting
Experience with downstream processes at lab, pilot, or production scale including chromatography (e.g. AKTA), tangential flow filtration, or nanofiltration
Knowledge in protein stability studies and routine protein analytical techniques
Strong technical writing and presentation skills
Job Overview:
The 2023 Co-Op will work in the downstream process development group of the drug substance function in Specialty Care Manufacturing Science and Analytical Technology (MSAT). The co-op will work in a laboratory setting on a project related to protein purification process characterization and protein drug substance stability. This position is 6 months on a full-time basis June/July 2023 – December 2023.
The drug substance function within global Manufacturing Science & Analytical Technology (MSAT) is the owner of Life Cycle Management (LCM) of DS Processes within Sanofi biologics manufacturing network. We deliver innovative, robust, and cost-effective next generation processes and provide commercial manufacturing support. The function is responsible for tech transfer activities including process fit-gap assessment, process validation, prepare dossier sections, & PAI support to enable launch of new and LCM products. Our expansive portfolio covers 17 products, 5 modalities, 3 expression systems within 12 internal and external global sites in US and EU. We will be supporting launch of 20 new products in next 5 years including monoclonal and multi-specific antibodies, fusion proteins, antibody-drug conjugates, synthorins and nanobodies. In recent years we have successfully established second-generation manufacturing process with a continuous process platform. We are pursuing future innovations such as digital labs, factories of future and advanced analytics-based process understanding and control.
Responsibilities:
Basic Qualifications:
Preferred Qualifications:
Sanofi Inc. and its U.S. affiliates are Equal Opportunity and Affirmative Action employers committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status; domestic violence victim status; atypical cellular or blood trait; genetic information (including the refusal to submit to genetic testing) or any other characteristic protected by law.
#GD-SG
#LI-GZAt Sanofi diversity and inclusion is foundational to how we operate and embedded in our Core Values. We recognize to truly tap into the richness diversity brings we must lead with inclusion and have a workplace where those differences can thrive and be leveraged to empower the lives of our colleagues, patients and customers. We respect and celebrate the diversity of our people, their backgrounds and experiences and provide equal opportunity for all.
About the company
Sanofi SA is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales.